文章摘要
姚卫格,舒继红.康复新液联合雷贝拉唑治疗咽喉反流的疗效分析[J].安徽医药,待发表.
康复新液联合雷贝拉唑治疗咽喉反流的疗效分析
投稿时间:2021-11-29  录用日期:2021-12-23
DOI:
中文关键词: 康复新液  雷贝拉唑  咽喉反流  治疗
英文关键词: 
基金项目:
作者单位邮编
姚卫格 蚌埠医学院第一附属医院 233004
舒继红 安徽省蚌埠市蚌埠医学院第一附属医院 
摘要点击次数: 178
全文下载次数: 0
中文摘要:
      目的 分析康复新液联合雷贝拉唑在治疗咽喉反流方面的临床疗效。方法 选取82例于2020年8月至2021年3月期间在蚌埠医学院第一附属医院门诊就诊的咽喉反流患者。随机分为两组,其中给予雷贝拉唑肠溶胶囊联合使用康复新液的为观察组;仅给予雷贝拉唑肠溶胶囊的为对照组。两组均连续用药8周,在用药4周及8周时分别比较两组的总有效率。结果 两组治疗前的年龄、性别、病程、RSI量表评分及RFS量表评分差异不具有统计学意义(P>0.05)。连续用药4周后,观察组的总有效率为65.0%、对照组总有效率为39.0%,连续用药8周后,观察组总有效率为87.5%,对照组总有效率为63.4%,观察组的两次疗效评价均高于对照组,且两组差异有统计学意义(P<0.05) 。结论 康复新液联合使用雷贝拉唑治疗咽喉反流有较好的临床效果,可在临床应用推广。
英文摘要:
      Objective To analysis the clinical efficacy of kangfuxin combined with rabeprazole in the treatment of laryngopharyngeal reflux. Methods 82 patients with LPR were selected from the Department of Otolaryngology, the First Affiliated Hospital of Bengbu Medical College from August 2020 to March 2021. They were randomly divided into two group, the observation group was given rabeprazole capsules combined with Kangfuxin, the control group was given rabeprazole capsules only. The total effective rate of the two groups were compared at 4 and 8 weeks. Results There was no significant difference in age, gender, course of disease, RSI and RFS between the two groups before treatment (P > 0.05). After 4 weeks of continuous medication, the total effective rate of the observation group was 65.0%, and that of the control group was 39.0%. After 8 weeks of continuous medication, the total effective rate of the observation group was 87.5%, and that of the control group was 63.4%. The two efficacy evaluations of the observation group were higher than those of the control group, and the difference between the two groups was statistically significant (P < 0.05). Conclusions Kangfuxin combined with rabeprazole has good clinical effect in the treatment of LPR, which can be popularized in clinical application.
  查看/发表评论  下载PDF阅读器
关闭

分享按钮